Skip to main content
NASDAQ:CKPT

Checkpoint Therapeutics News Headlines

$2.30
-0.08 (-3.36 %)
(As of 05/14/2021 01:41 PM ET)
Add
Compare
Today's Range
$2.29
$2.41
50-Day Range
$2.36
$3.21
52-Week Range
$1.56
$5.38
Volume12,722 shs
Average Volume1.29 million shs
Market Capitalization$172.99 million
P/E RatioN/A
Dividend YieldN/A
Beta1.66

Headlines

Checkpoint Therapeutics (NASDAQ CKPT) News Headlines Today

SourceHeadline
What Is The Ownership Structure Like For Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)?What Is The Ownership Structure Like For Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)?
finance.yahoo.com - May 8 at 12:50 PM
Checkpoint Therapeutics (NASDAQ:CKPT) Issues Quarterly  Earnings ResultsCheckpoint Therapeutics (NASDAQ:CKPT) Issues Quarterly Earnings Results
americanbankingnews.com - May 7 at 3:14 PM
Checkpoint Therapeutics, Inc. to Post FY2022 Earnings of ($0.67) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:CKPT)Checkpoint Therapeutics, Inc. to Post FY2022 Earnings of ($0.67) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:CKPT)
americanbankingnews.com - May 7 at 9:24 AM
Checkpoint Capital, LLC Appoints Wanda Stevens as Director of Business DevelopmentCheckpoint Capital, LLC Appoints Wanda Stevens as Director of Business Development
businesswire.com - May 4 at 5:40 PM
The Checkpoint Therapeutics (NASDAQ:CKPT) Share Price Is Up 80% And Shareholders Are Holding OnThe Checkpoint Therapeutics (NASDAQ:CKPT) Share Price Is Up 80% And Shareholders Are Holding On
nasdaq.com - April 23 at 12:31 PM
Did You Miss Checkpoint Therapeutics (NASDAQ:CKPT) 84% Share Price Gain?Did You Miss Checkpoint Therapeutics' (NASDAQ:CKPT) 84% Share Price Gain?
finance.yahoo.com - March 9 at 8:01 AM
Checkpoint Therapeutics forms a scientific advisory boardCheckpoint Therapeutics forms a scientific advisory board
seekingalpha.com - March 4 at 5:25 PM
Wildomar DUI Checkpoint ResultsWildomar DUI Checkpoint Results
msn.com - March 1 at 5:53 PM
What led Checkpoint Inhibitors for Treating Cancer Market 2025 to mark 18670 Million USD with CAGR of 24.5 %What led Checkpoint Inhibitors for Treating Cancer Market 2025 to mark 18670 Million USD with CAGR of 24.5 %
marketwatch.com - February 24 at 1:28 PM
Checkpoint Inhibitors for Treating Cancer Market Application, Product, Sales and Forecast 2020-2027 Report By Ameco ResearchCheckpoint Inhibitors for Treating Cancer Market Application, Product, Sales and Forecast 2020-2027 Report By Ameco Research
marketwatch.com - February 24 at 7:59 AM
DUI Checkpoint Announced For WildomarDUI Checkpoint Announced For Wildomar
msn.com - February 23 at 12:57 PM
44 Citations Issued At DUI Checkpoint In Lake Elsinore44 Citations Issued At DUI Checkpoint In Lake Elsinore
msn.com - February 22 at 3:11 PM
[Opinion] Im Just a Country Boy: Man Arrested Near Inauguration Checkpoint With Guns, Ammunition and Unauthorized Credentials Pleads Ignorance[Opinion] 'I'm Just a Country Boy': Man Arrested Near Inauguration Checkpoint With Guns, Ammunition and Unauthorized Credentials Pleads Ignorance
msn.com - January 17 at 6:47 PM
Woman Drove Up to Inauguration Checkpoint, Claimed to Be ‘Part of the Presidential Cabinet’: PoliceWoman Drove Up to Inauguration Checkpoint, Claimed to Be ‘Part of the Presidential Cabinet’: Police
msn.com - January 17 at 6:47 PM
Checkpoint Therapeutics to Participate in Three January 2021 Virtual Investor ConferencesCheckpoint Therapeutics to Participate in Three January 2021 Virtual Investor Conferences
finance.yahoo.com - January 6 at 9:55 AM
mce Enters into a Strategic Agreement with Checkpointmce Enters into a Strategic Agreement with Checkpoint
benzinga.com - January 5 at 7:37 PM
Man charged with stuffing four kittens in pants in botched smuggling attempt at Tuas CheckpointMan charged with stuffing four kittens in pants in botched smuggling attempt at Tuas Checkpoint
msn.com - December 24 at 11:36 PM
Heres Why Were Not Too Worried About Checkpoint Therapeutics (NASDAQ:CKPT) Cash Burn SituationHere's Why We're Not Too Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Situation
finance.yahoo.com - December 9 at 9:30 AM
Is Checkpoint Therapeutics, Inc. (CKPT) A Good Stock To Buy?Is Checkpoint Therapeutics, Inc. (CKPT) A Good Stock To Buy?
finance.yahoo.com - November 27 at 2:01 PM
Checkpoint Therapeutics Announces Presentation of Updated Cosibelimab Lung Cancer Results at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual MeetingCheckpoint Therapeutics Announces Presentation of Updated Cosibelimab Lung Cancer Results at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
finance.yahoo.com - November 9 at 9:12 AM
Checkpoint Therapeutics +10% after expanding cosibelimab manufacturing deal with Samsung BiologicsCheckpoint Therapeutics +10% after expanding cosibelimab manufacturing deal with Samsung Biologics
seekingalpha.com - November 2 at 8:22 AM
What Kind Of Shareholders Hold The Majority In Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) Shares?What Kind Of Shareholders Hold The Majority In Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) Shares?
finance.yahoo.com - October 25 at 10:18 AM
How Much Did Checkpoint Therapeutics'(NASDAQ:CKPT) Shareholders Earn From Share Price Movements Over The Last Three Years?How Much Did Checkpoint Therapeutics'(NASDAQ:CKPT) Shareholders Earn From Share Price Movements Over The Last Three Years?
finance.yahoo.com - September 19 at 3:09 PM
Checkpoint Therapeutics announces $20M bought deal offeringCheckpoint Therapeutics announces $20M bought deal offering
seekingalpha.com - September 17 at 6:01 PM
Checkpoint Therapeutics Announces $20.0 Million Bought Deal OfferingCheckpoint Therapeutics Announces $20.0 Million Bought Deal Offering
finance.yahoo.com - September 17 at 6:01 PM
Checkpoint Therapeutics cosibelimab shows encouraging action in skin cancer studyCheckpoint Therapeutics' cosibelimab shows encouraging action in skin cancer study
seekingalpha.com - September 17 at 8:00 AM
Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell CarcinomaCheckpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma
finance.yahoo.com - September 17 at 8:00 AM
Checkpoint Therapeutics To Release Significant Drug Data At This Weeks ESMO CongressCheckpoint Therapeutics To Release Significant Drug Data At This Week's ESMO Congress
finance.yahoo.com - September 14 at 10:28 PM
Checkpoint Therapeutics To Release Significant Drug Data At This Week's ESMO CongressCheckpoint Therapeutics To Release Significant Drug Data At This Week's ESMO Congress
finance.yahoo.com - September 14 at 12:27 PM
Checkpoint (CKPT) Hits Yearly High, Will The Rally Sustain?Checkpoint (CKPT) Hits Yearly High, Will The Rally Sustain?
nasdaq.com - September 14 at 7:27 AM
Check Checkpoint (CKPT) Hits Yearly High, Will The Rally Sustain?Check Checkpoint (CKPT) Hits Yearly High, Will The Rally Sustain?
markets.businessinsider.com - September 14 at 2:24 AM
Main Streets Six-Month CheckpointMain Street's Six-Month Checkpoint
pymnts.com - September 11 at 7:31 AM
Checkpoint Therapeutics to Participate in Three September 2020 Virtual Investor ConferencesCheckpoint Therapeutics to Participate in Three September 2020 Virtual Investor Conferences
finance.yahoo.com - September 10 at 10:21 AM
Virginia continues Checkpoint Strikeforce campaign to end drunk drivingVirginia continues Checkpoint Strikeforce campaign to end drunk driving
msn.com - August 26 at 6:50 PM
Checkpoint Therapeutics EPS in-line, misses on revenueCheckpoint Therapeutics EPS in-line, misses on revenue
seekingalpha.com - August 5 at 8:10 PM
Checkpoint Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate HighlightsCheckpoint Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
finance.yahoo.com - August 5 at 8:10 PM
What We Learned About Checkpoint Therapeutics (NASDAQ:CKPT) CEO PayWhat We Learned About Checkpoint Therapeutics' (NASDAQ:CKPT) CEO Pay
finance.yahoo.com - July 21 at 7:35 AM
What We Learned About Checkpoint Therapeutics' (NASDAQ:CKPT) CEO PayWhat We Learned About Checkpoint Therapeutics' (NASDAQ:CKPT) CEO Pay
finance.yahoo.com - July 21 at 7:35 AM
Stock Alert: Checkpoint Therapeutics CKPT Up 45%Stock Alert: Checkpoint Therapeutics CKPT Up 45%
www.nasdaq.com - July 17 at 1:33 PM
3 “Strong Buy” Penny Stocks That Could Rally to $10 (Or More)3 “Strong Buy” Penny Stocks That Could Rally to $10 (Or More)
finance.yahoo.com - July 16 at 6:05 PM
Soldier at Auno Checkpoint: “To hell with democracy, useless democracy”, causes fatal crashSoldier at Auno Checkpoint: “To hell with democracy, useless democracy”, causes fatal crash
www.msn.com - June 14 at 1:06 AM
Checkpoint Therapeutics CEO On Tapping Into A $25 Billion Cancer Treatment MarketCheckpoint Therapeutics CEO On Tapping Into A $25 Billion Cancer Treatment Market
finance.yahoo.com - May 20 at 1:43 PM
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesCheckpoint Therapeutics, Inc. (NASDAQ:CKPT) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
finance.yahoo.com - May 9 at 5:02 PM
Checkpoint Therapeutics EPS beats by $0.07, beats on revenueCheckpoint Therapeutics EPS beats by $0.07, beats on revenue
seekingalpha.com - May 7 at 5:03 AM
Checkpoint Capital, LLC Expands Leadership Team With Two Seasoned Bank PM’sCheckpoint Capital, LLC Expands Leadership Team With Two Seasoned Bank PM’s
www.businesswire.com - May 4 at 12:42 PM
mmune Checkpoint Inhibitors Market Analysis By Industry Size, Share, Revenue Growth, Development and Demand Forecast To 2025mmune Checkpoint Inhibitors Market Analysis By Industry Size, Share, Revenue Growth, Development and Demand Forecast To 2025
www.marketwatch.com - April 28 at 10:58 AM
Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Invest In Growth?Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Invest In Growth?
finance.yahoo.com - April 27 at 8:45 AM
INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Checkpoint Therapeutics, Inc. for Potential Breach of Fiduciary Duty ClaimsINVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Checkpoint Therapeutics, Inc. for Potential Breach of Fiduciary Duty Claims
finance.yahoo.com - April 27 at 8:45 AM
Checkpoint Therapeutics nabs new patent in U.S.Checkpoint Therapeutics nabs new patent in U.S.
seekingalpha.com - April 21 at 11:08 AM
Immuno-oncology: Focus on Developments and Opportunities in Immune Checkpoint ModulatorsImmuno-oncology: Focus on Developments and Opportunities in Immune Checkpoint Modulators
finance.yahoo.com - April 16 at 8:05 PM
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.